Abstract
The introduction of multi-agent chemotherapy dramatically improved the outcome for patients with osteosarcoma. However, we appear to have reached a plateau in outcome with a long-term event-free survival of 60-70%. Therefore, detection of further improvements will likely require larger numbers of patients. This goal is best achieved via randomized clinical trials (RCTs) requiring large-scale cooperation and collaboration. With this background, four multinational groups agreed on the merits of collaboration: Children’s Oncology Group (COG), Cooperative Osteosarcoma Study Group (COSS), European Osteosarcoma Intergroup (EOI) and Scandinavian Sarcoma Group (SSG); they designed a study to determine whether altering postoperative therapy based on histological response improved the outcome. The study design includes a backbone of 10 weeks of preoperative therapy using MAP (methotrexate, Adriamycin and cisplatin). Following surgery, patients are stratified according to histological response. Patients classified as “good responders” (≥90% necrosis) are randomized to continue MAP or to receive MAP followed by maintenance pegylated interferon, while “poor responders” (<90% necrosis) are randomized to either continue MAP or to receive MAPIE (MAP+ifosfamide, etoposide). The design includes the registration of 1,400 patients over 4 years as well as the evaluation of quality of life using two different instruments. The group has established an efficient infrastructure to ensure successful implementation of the trial. This has included the EURAMOS Intergroup Safety Desk, which has established an international system for SAE, SAR and SUSAR reporting to the relevant competent authorities and ethics committees for each participating country. The group has also developed trial site monitoring and data center audits with funding from the European Science Foundation (ESF). The ESF has also funded three training courses to familiarize institutional staff with the requirements of multinational GCP trials. We have established a successful collaboration, and as of February 2008, 901 patients have been enrolled (COG 448; COSS 226; EOI 181; SSG 46) from 249 institutions in 16 different countries. As expected, 80% of the patients are <18 years of age, and accrual into the Quality of Life sub-study is proceeding as planned with 90% of the subjects agreeing to participate. International awareness is increasing and procedures for applicant countries wishing to join the collaboration have been implemented. Details about EURAMOS can be found at www.euramos.org. International trials in rare diseases are practicable with appropriate funding, planning and support. Although the implementation of such trials is difficult and time consuming, it is a worthwhile effort to rapidly complete RCTs and identify interventions that will improve the outcome of all osteosarcoma patients.EURAMOS-1 is the fastest accruing osteosarcoma trial and is already the largest osteosarcoma study conducted.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Bibliography
Friedman MA, Carter SK. The therapy of osteogenic sarcoma: current status and thoughts for the future. J Surg Oncol. 1972;4:482-510.
Marcove RC, Mike V, Hajek JV, et al. Osteogenic sarcoma under the age of twenty-one. A review of one hundred and forty-five operative cases. J Bone Joint Surg [Am]. 1970;52:411-423.
Weinfeld MS, Dudley HR. Osteogenic sarcoma: a follow-up study of the ninety-four cases observed at the Massachusetts General Hospital from 1920 to 1960. J Bone Joint Surg [Am]. 1962;44A:269-276.
Dahlin DC, Coventry MB. Osteogenic sarcoma. A study of six hundred cases. J Bone Joint Surg [Am]. 1967;49:101-110.
Ochs JJ, Freeman AI, Douglass HO, et al. cis-Dichlorodiammineplatinum (II) in advanced osteogenic sarcoma. Cancer Treat Rep. 1978;62:239-245.
Gasparini M, Rouesse J, van Oosterom A, et al. Phase II study of cisplatin in advanced osteogenic sarcoma. European Organization for Research on Treatment of Cancer: Soft Tissue and Bone Sarcoma Group. Cancer Treat Rep. 1985;69:211-213.
Baum ES, Gaynon P, Greenberg L, et al. Phase II trail cisplatin in refractory childhood cancer: Children’s Cancer Study Group Report. Cancer Treat Rep. 1981;65:815-822.
Pratt CB, Shanks EC. Doxorubicin in treatment of malignant solid tumors in children. Am J Dis Child. 1974;127:534-536.
Cortes EP, Holland JF, Wang JJ, et al. Amputation and adriamycin in primary osteosarcoma. N Engl J Med. 1974;291:998-1000.
Jaffe N, Frei E, Traggis D, et al. Adjuvant methotrexate and citrovorum-factor treatment of osteogenic sarcoma. N Engl J Med. 1974;291:994-997.
Pratt CB, Howarth C, Ransom JL, et al. High-dose methotrexate used alone and in combination for measurable primary or metastatic osteosarcoma. Cancer Treat Rep. 1980;64:11-20.
Pratt CB, Roberts D, Shanks EC, et al. Clinical trials and pharmacokinetics of intermittent high-dose methotrexate-”leucovorin rescue” for children with malignant tumors. Cancer Res. 1974;34:3326-3331.
Harris MB, Cantor AB, Goorin AM, et al. Treatment of osteosarcoma with ifosfamide: comparison of response in pediatric patients with recurrent disease with patients previously untreated− A Pediatric Oncology Group study. Med Pediatr Oncol. 1995;24:87-92.
Goorin AM, Harris MB, Bernstein M, et al. Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. J Clin Oncol. 2002;20:426-433.
Pratt C, Shanks E, Hustu O, et al. Adjuvant multiple drug chemotherapy for osteosarcoma of the extremity. Cancer. 1977;39:51-57.
Pratt CB, Rivera G, Shanks E, et al. Combination chemotherapy for osteosarcoma. Cancer Treat Rep. 1978;62:251-257.
Sutow WW, Gehan EA, Dyment PG, et al. Multidrug adjuvant chemotherapy for osteosarcoma: interim report of the Southwest Oncology Group Studies. Cancer Treat Rep. 1978;62:265-269.
Sutow WW, Sullivan MP, Fernbach DJ, et al. Adjuvant chemotherapy in primary treatment of osteogenic sarcoma. A Southwest Oncology Group study. Cancer. 1975;36:1598-1602.
Goorin AM, Frei E III, Abelson HT. Adjuvant chemotherapy for osteosarcoma: a decade of experience. Surg Clin North Am. 1981;61:1379-1389.
Taylor WF, Ivins JC, Pritchard DJ, et al. Trends and variability in survival among patients with osteosarcoma: a 7-year update. Mayo Clin Proc. 1985;60:91-104.
Carter SK. Adjuvant chemotherapy in osteogenic sarcoma: the triumph that isn’t? J Clin Oncol. 1984;2:147-148.
Edmonson JH, Green SJ, Ivins JC, et al. A controlled pilot study of high-dose methotrexate as postsurgical adjuvant treatment for primary osteosarcoma. J Clin Oncol. 1984;2:152-156.
Eilber F, Giuliano A, Eckardt J, et al. Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. J Clin Oncol. 1987;5:21-26.
Link MP, Goorin AM, Miser AW, et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med. 1986;314:1600-1606.
Rosen G, Marcove RC, Caparros B, et al. Primary osteogenic sarcoma: the rationale for preoperative chemotherapy and delayed surgery. Cancer. 1979;43:2163-2177.
Rosen G, Murphy ML, Huvos AG, et al. Chemotherapy, en bloc resection, and prosthetic bone replacement in the treatment of osteogenic sarcoma. Cancer. 1976;37:1-11.
Winkler K, Beron G, Delling G, et al. Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol. 1988;6:329-337.
Provisor AJ, Ettinger LJ, Nachman JB, et al. Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children’s Cancer Group. J Clin Oncol. 1997;15:76-84.
Bacci G, Picci P, Ruggieri P, et al. Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for osteosarcoma of the extremities. The Istituto Rizzoli Experience in 127 patients treated preoperatively with intravenous methotrexate (high versus moderate doses) and intra-arterial cisplatin. Cancer. 1990;65:2539-2553.
Goorin AM, Schwartzentruber DJ, Devidas M, et al. Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. J Clin Oncol. 2003;21:1574-1580.
Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002;20:776-790.
Meyers PA, Schwartz CL, Krailo M, et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol. 2005;23:2004-2011.
Lewis IJ, Nooij MA, Whelan J, et al. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst. 2007;99:112-128.
Ferrari S, Smeland S, Mercuri M, et al. Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol. 2005;23:8845-8852.
Rosen G, Caparros B, Huvos AG, et al. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer. 1982;49:1221-1230.
Meyers PA, Heller G, Healey J, et al. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol. 1992;10:5-15. [see comments].
Meyers PA, Gorlick R, Heller G, et al. Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol. J Clin Oncol. 1998;16:2452-2458.
Winkler K, Beron G, Kotz R, et al. Neoadjuvant chemotherapy for osteogenic sarcoma: results of a Cooperative German/Austrian study. J Clin Oncol. 1984;2:617-624.
Fuchs N, Bielack SS, Epler D, et al. Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group’s protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol. 1998;9:893-899.
Jaffe N, Knapp J, Chuang VP, et al. Osteosarcoma: intra-arterial treatment of the primary tumor with cis-diammine-dichloroplatinum II (CDP). Angiographic, pathologic, and pharmacologic studies. Cancer. 1983;51:402-407.
Jaffe N, Robertson R, Ayala A, et al. Comparison of intra-arterial cis-diamminedichloroplatinum II with high-dose methotrexate and citrovorum factor rescue in the treatment of primary osteosarcoma. J Clin Oncol. 1985;3:1101-1104.
Winkler K, Bielack S, Delling G, et al. Effect of intra-arterial versus intravenous cisplatin in addition to systemic doxorubicin, high-dose methotrexate, and ifosfamide on histologic tumor response in osteosarcoma (study COSS-86). Cancer. 1990;66:1703-1710.
Souhami RL, Craft AW, Van der Eijken JW, et al. Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. Lancet. 1997;350:911-917.
Bramwell VH, Burgers M, Sneath R, et al. A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup. J Clin Oncol. 1992;10:1579-1591.
Bacci G, Ferrari S, Delepine N, et al. Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin. J Clin Oncol. 1998;16:658-663.
Saeter G, Alvegard TA, Elomaa I, et al. Treatment of osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of preoperative chemotherapy with single-agent high-dose methotrexate: a Scandinavian Sarcoma Group study. J Clin Oncol. 1991;9:1766-1775.
Smeland S, Muller C, Alvegard TA, et al. Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders. Eur J Cancer. 2003;39:488-494.
Meyers PA, Schwartz CL, Krailo MD, et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival – a report from the Children’s Oncology Group. J Clin Oncol. 2008;26:633-638.
Harris MB, Gieser P, Goorin AM, et al. Treatment of metastatic osteosarcoma at diagnosis: a Pediatric Oncology Group Study. J Clin Oncol. 1998;16:3641-3648.
Bacci G, Picci P, Ferrari S, et al. Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities: results of 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin. Cancer. 1993;72:3227-3238.
Strander H, Einhorn S. Effect of human leukocyte interferon on the growth of human osteosarcoma cells in tissue culture. Int J Cancer. 1977;19:468-473.
Brosjo O, Bauer HC, Brostrom LA, et al. Influence of human alpha-interferon on four human osteosarcoma xenografts in nude mice. Cancer Res. 1985;45:5598-5602.
Bauer HC, Brosjo O, Strander H. Comparison of the growth inhibiting effect of natural and recombinant interferon-alpha on human osteosarcomas in nude mice. J Interferon Res. 1987;7:365-369.
Allen IE, Ross SD, Borden SP, et al. Meta-analysis to assess the efficacy of interferon-alpha in patients with follicular non-Hodgkin’s lymphoma. J Immunother. 2001;24:58-65.
Bjorkstrand B, Svensson H, Goldschmidt H, et al. Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: a retrospective registry study from the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2001;27:511-515.
Strander H, Bauer HC, Brosjo O, et al. Long-term adjuvant interferon treatment of human osteosarcoma. A pilot study. Acta Oncol. 1995;34:877-880.
Bukowski R, Ernstoff MS, Gore ME, et al. Pegylated interferon alfa-2b treatment for patients with solid tumors: a phase I/II study. J Clin Oncol. 2002;20:3841-3849.
Bunn S, Kelly D, Murray KF. Safety, efficacy and pharmacokinetics of interferon alfa-2b and ribavirin in children with chronic hepatitis C. J Hepatol. 2000;32:763.
Wozniakowska-Gesicka T, Wisniewska-Ligier M, Kups J, et al. Influence of interferon-alpha therapy on the count and function of T lymphocytes in children with chronic hepatitis C. Pol Merkur Lekarski. 2001;11:344-347.
Bhatia S, Landier W, Robison L. Late effects of childhood cancer therapy. In: DeVita V, Hellman S, Rosenberg S, eds. Progress in Oncology 2002. Sudbury: Jone and Barlett Publications; 2003:171-201.
Hudson MM, Tyc VL, Cremer LK, et al. Patient satisfaction after limb-sparing surgery and amputation for pediatric malignant bone tumors. J Pediatr Oncol Nurs. 1998;15:60-69. discussion 70-71.
Nicholson HS, Mulvihill JJ, Byrne J. Late effects of therapy in adult survivors of osteosarcoma and Ewing’s sarcoma. Med Pediatr Oncol. 1992;20:6-12.
Postma A, Kingma A, De Ruiter JH, et al. Quality of life in bone tumor patients comparing limb salvage and amputation of the lower extremity. J Surg Oncol. 1992;51:47-51.
Weddington WW. Psychological outcomes in survivors of extremity sarcomas following amputation or limb-sparing surgery. Cancer Treat Res. 1991;56:53-60.
Calaminus G, Weinspach S, Teske C, et al. Quality of life in children and adolescents with cancer. First results of an evaluation of 49 patients with the PEDQOL questionnaire. Klin Padiatr. 2000;212:211-215.
Varni JW, Burwinkle TM, Katz ER, et al. The PedsQL in pediatric cancer: reliability and validity of the Pediatric Quality of Life Inventory Generic Core Scales, Multidimensional Fatigue Scale, and Cancer Module. Cancer. 2002;94:2090-2106.
Nagarajan R, Neglia JP, Clohisy DR, et al. Limb salvage and amputation in survivors of pediatric lower-extremity bone tumors: what are the long-term implications? J Clin Oncol. 2002;20:4493-4501.
Wilhelmsen L. Role of the Data and Safety Monitoring Committee (DSMC). Stat Med. 2002;21:2823-2829.
DeMets DL, Yusuf S. The Data and Safety Monitoring Committee: some final thoughts. Am Heart J. 2001;141:548-549.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Marina, N. et al. (2009). International Collaboration is Feasible in Trials for Rare Conditions: The EURAMOS Experience. In: Jaffe, N., Bruland, O., Bielack, S. (eds) Pediatric and Adolescent Osteosarcoma. Cancer Treatment and Research, vol 152. Springer, Boston, MA. https://doi.org/10.1007/978-1-4419-0284-9_18
Download citation
DOI: https://doi.org/10.1007/978-1-4419-0284-9_18
Published:
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4419-0283-2
Online ISBN: 978-1-4419-0284-9
eBook Packages: MedicineMedicine (R0)